- Home
- IMOS vs CRGX Comparison
IMOS vs CRGX Comparison
Compare IMOS & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMOS
- CRGX
- Stock Information
- Founded
- IMOS 1997
- CRGX 2021
- Country
- IMOS Taiwan
- CRGX United States
- Employees
- IMOS N/A
- CRGX N/A
- Industry
- IMOS Semiconductors
- CRGX
- Sector
- IMOS Technology
- CRGX
- Exchange
- IMOS Nasdaq
- CRGX Nasdaq
- Market Cap
- IMOS 813.1M
- CRGX 964.5M
- IPO Year
- IMOS N/A
- CRGX 2023
- Fundamental
- Price
- IMOS $19.19
- CRGX $14.02
- Analyst Decision
- IMOS
- CRGX Strong Buy
- Analyst Count
- IMOS 0
- CRGX 6
- Target Price
- IMOS N/A
- CRGX $31.80
- AVG Volume (30 Days)
- IMOS 27.3K
- CRGX 237.0K
- Earning Date
- IMOS 11-05-2024
- CRGX 11-12-2024
- Dividend Yield
- IMOS 6.10%
- CRGX N/A
- EPS Growth
- IMOS 7.03
- CRGX N/A
- EPS
- IMOS 0.07
- CRGX N/A
- Revenue
- IMOS $724,842,895.00
- CRGX N/A
- Revenue This Year
- IMOS $15.65
- CRGX N/A
- Revenue Next Year
- IMOS $13.49
- CRGX N/A
- P/E Ratio
- IMOS $12.84
- CRGX N/A
- Revenue Growth
- IMOS 13.31
- CRGX N/A
- 52 Week Low
- IMOS $18.20
- CRGX $13.33
- 52 Week High
- IMOS $32.19
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- IMOS 42.28
- CRGX 38.60
- Support Level
- IMOS $18.20
- CRGX $13.33
- Resistance Level
- IMOS $19.40
- CRGX $15.26
- Average True Range (ATR)
- IMOS 0.24
- CRGX 1.22
- MACD
- IMOS 0.01
- CRGX -0.17
- Stochastic Oscillator
- IMOS 55.88
- CRGX 27.33
About IMOS ChipMOS TECHNOLOGIES INC.
ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. The Company derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.